Neurotoxin Dosing & Reconstitution 2026: SOPs for Botox, Dysport, Jeuveau & Daxxify

Four FDA-approved neurotoxins now dominate the aesthetic market: Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Jeuveau (prabotulinumtoxinA), and Daxxify (daxibotulinumtoxinA). They are frequently discussed as if they were the same drug in different boxes. They are not. Each is manufactured differently, formulated differently, and — most consequentially for an operator — measured in units that are calibrated to its own potency assay. A unit of one is not a unit of another.

That single fact is the root of most neurotoxin dosing errors, and it is why inconsistent reconstitution and dosing documentation has become one of the most common findings in med spa chart audits and one of the easier points for a plaintiff attorney to exploit. This guide is not a how-to on facial injection technique — that is the clinician's domain and your medical director's responsibility. It is the standardization and documentation layer: how to reconstitute consistently, how to label and store correctly, how long a reconstituted vial is good for, how to handle vials between patients, and exactly what every dose record must contain so your practice can prove consistency and defend an outcome.

Why Neurotoxin Standardization Is a Compliance Issue

Neurotoxin injection is the highest-volume clinical service in most med spas, which means it is also the highest-frequency opportunity for a documentation gap to repeat itself hundreds of times before anyone notices. When the way a vial is reconstituted, labeled, and charted depends on which provider happened to be working that day, you do not have a protocol — you have a collection of personal habits. Regulators and litigators treat the difference as meaningful.

It helps to separate two things that often get conflated. Clinical judgment — how much product a given face needs, where to place it, how to assess the result — belongs to the licensed injector and the medical director, and this guide does not touch it. Standardization — which diluent the practice uses, how a vial is labeled, how long it is good for, what gets charted — is an operational system that should be identical no matter who is working. Conflating the two is how practices end up believing they cannot standardize because "every patient is different." Patients differ; the diluent, the labeling rule, and the documentation template do not. Drawing that line clearly is the first job of a neurotoxin SOP.

The documentation auditors and attorneys ask for first

When a board investigator or a plaintiff's expert reviews a neurotoxin practice, they are not initially looking at injection skill. They are looking at the paper trail: Can you show which lot of which product went into which patient? Can you show the diluent and dilution volume used? Can you show the vial was within its beyond-use date at the time of treatment? Can you show the same reconstitution standard was applied across providers? If those answers live only in someone's memory, the record is not defensible. A written SOP plus a standardized dosing template is what converts routine clinical work into evidence that the standard of care was met.

Where inconsistency turns into liability

Inconsistency creates exposure in three predictable ways. First, dosing errors from brand confusion — charting "30 units" without recording which product means the next provider, or an investigator, cannot reconstruct whether the dose was appropriate. Second, dilution drift — when providers reconstitute the same product to different concentrations, the spread and effect vary, outcomes become unpredictable, and complications are harder to explain. Third, traceability failure — if a product is recalled or an adverse event occurs, an inability to tie a dose to a specific lot number is both a patient-safety problem and a Drug Supply Chain Security Act concern. Each of these is preventable with documentation discipline rather than clinical heroics.

For the broader documentation backbone these protocols sit inside, see our guide on the med spa policy and procedure manual, and for product-handling traceability specifically, our overview of DSCSA compliance for med spas.

The Four Major Neurotoxins in 2026

All four are botulinum toxin type A products that temporarily reduce muscle activity, and all are supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use. From a standardization standpoint, what matters is that each has its own vial sizes, its own unit scale, and its own labeling for storage and handling. Your SOP should carry a short brand-specific section for every product your practice actually stocks. The table below summarizes the operator-relevant differences — not as a dosing prescription, but as the kind of at-a-glance reference that belongs near the reconstitution station.

Notice that the only product breaking the refrigeration pattern is Daxxify, and the only product dosed near Botox's scale is Jeuveau. Those two exceptions account for a disproportionate share of handling and dosing mistakes, which is why a written reference matters more than staff memory. The figures here are operator orientation, not clinical dosing — the exact units, ratios, and dilution any provider uses must come from current FDA labeling and your medical director's written protocol.

Botox (onabotulinumtoxinA)

Botox is the longest-marketed and most familiar product, commonly supplied in 50-unit and 100-unit vials. Its prescribing information directs reconstitution with sterile, preservative-free 0.9% sodium chloride, refrigerated storage of unopened vials at 2°C to 8°C, and administration within 24 hours of reconstitution. Because Botox is the reference point most clinicians dose against, it is usually the anchor brand in a practice's unit-equivalence reference.

Dysport (abobotulinumtoxinA)

Dysport is supplied in 300-unit and 500-unit vials and is known for a somewhat wider field of diffusion, which some clinicians use to advantage in larger muscle areas. Its 300-unit vial is reconstituted with preservative-free saline per labeling, refrigerated, and used within 24 hours. The critical operator-level fact is that Dysport units are numerically much smaller than Botox units — the conversion is the single most error-prone number in a neurotoxin practice.

Jeuveau (prabotulinumtoxinA)

Jeuveau is supplied in a single-dose 100-unit vial and, per its labeling, is reconstituted with preservative-free 0.9% sodium chloride — for example, 2.5 mL to reach a concentration of 4 units per 0.1 mL. It is marketed primarily for glabellar lines and is dosed at approximately a 1:1 relationship with Botox, which makes it the easiest of the alternatives to fold into an existing Botox-anchored protocol — but "approximately" is doing real work in that sentence, and it should never be treated as exactly identical.

Daxxify (daxibotulinumtoxinA)

Daxxify is the newest of the four and the most distinct. It is formulated with a stabilizing peptide rather than human serum albumin, is reported to deliver a longer duration of effect for many patients, and — uniquely among these products — may be stored unopened at room temperature (20°C to 25°C) or refrigerated, in its original carton to protect from light. It uses its own unit scale and its own dosing, and its labeling is explicit that each reconstituted vial is for a single patient in a single injection session. Daxxify deserves its own clearly separated section in any SOP precisely because its handling rules break the patterns staff learn from the other three.

Unit Equivalence: Why Brands Are Not Interchangeable

The most important sentence in this entire guide: one unit of one neurotoxin is not equivalent to one unit of another. Each manufacturer defines a "unit" using its own proprietary potency assay, so the numbers measure different things. This is why a unit-equivalence reference — vetted by your medical director and printed where injectors work — belongs in every neurotoxin SOP. It is not a clinical dosing prescription; it is a standardization tool that prevents the most common and most dangerous category of error: assuming the numbers transfer.

The Botox-to-Dysport conversion (2.5–3:1)

The most widely cited clinical conversion between Botox and Dysport is approximately 2.5 to 3 units of Dysport for every 1 unit of Botox, with 2.5:1 the figure many practices adopt. The range exists because individual clinicians and published sources differ slightly, and because patient anatomy matters. For standardization purposes, your practice should pick one ratio, have the medical director approve it, write it down, and require that the brand and the units actually administered both be charted. A note that reads "Dysport, 2.5:1 conversion, 60 units to glabella/forehead" is defensible; a note that reads "60 units" is not.

Jeuveau's near 1:1 relationship with Botox

Jeuveau is generally dosed at roughly a 1:1 ratio with Botox, which is convenient but carries its own trap: because it feels interchangeable, providers may stop recording which product was used. Standardization here means documenting the brand on every chart even when the numbers happen to match Botox, so that traceability and lot tracking are never lost to the assumption of equivalence.

Daxxify's different scale and longer duration

Daxxify uses its own unit scale and cannot be converted one-to-one to Botox units. Its reported longer duration also changes the patient conversation and the re-treatment interval, which means consent and follow-up documentation should reflect the product specifically. Because Daxxify is newer, staff are most likely to mishandle it — both in dosing assumptions and in storage — so the SOP should call it out explicitly rather than lumping it with "neurotoxins" generally. For the equivalence question patients ask most, our companion piece on who can legally inject Botox in the United States covers the scope-of-practice side.

Reconstitution and Dilution Conventions

Reconstitution is where standardization either happens or falls apart. All four products are reconstituted with sterile 0.9% sodium chloride, but the diluent type, the volume, and the technique all introduce variation if they are not fixed by protocol. The goal of the SOP is simple: every provider, every time, reconstitutes a given product to the same concentration using the same diluent and the same gentle technique, and records what they did.

Diluent: preserved vs preservative-free saline

The neurotoxin prescribing information — Botox's in particular — specifies preservative-free 0.9% sodium chloride. In practice, many injectors reconstitute with preserved (bacteriostatic) saline off-label because the benzyl alcohol preservative reduces injection-site stinging and there is published support for comfort benefits. This is a legitimate clinical choice, but it is a choice your medical director must make deliberately and document — not something each provider decides ad hoc. Your SOP should state which diluent the practice uses, acknowledge when it departs from the label, and require that the diluent type be recorded with each reconstitution. Mixing conventions between providers is exactly the kind of inconsistency an audit flags.

How dilution volume changes spread and diffusion

The volume of saline used to reconstitute a vial determines the final concentration, and concentration influences how the product spreads through tissue. A more dilute preparation (larger saline volume) tends to diffuse over a wider area; a more concentrated preparation stays more localized. Neither is inherently right — but if two providers reconstitute the same 100-unit vial to different volumes, they are effectively delivering a different product, and outcomes will vary in ways that are hard to explain after the fact. Standardizing the dilution volume per product, recording it on the vial label and in the chart, and reconstituting with gentle technique (the toxin is a fragile protein) is the core of reconstitution consistency. The resulting concentration — units per 0.1 mL — should be a known, written number for every product you stock.

A worked example makes the point concrete. Reconstituting a 100-unit Botox vial with 2.5 mL of saline yields 4 units per 0.1 mL; the same vial reconstituted with 4 mL yields 2.5 units per 0.1 mL. Both are valid, but they are not the same preparation, and a chart that records "Botox 4 units to each glabellar point" means something different under each. The fix is not to mandate one universal volume across the industry — it is to mandate one volume per product within your practice, publish the resulting concentration, and require providers to chart the volume they actually used. Standardization is internal consistency plus documentation, not conformity to an outside number.

Reconstitution technique itself should also be standardized, because botulinum toxin is a delicate protein that can be denatured by rough handling. The SOP should direct that saline be introduced slowly down the vial wall rather than forcefully injected onto the powder, that the vial be swirled gently rather than shaken, and that the reconstituted solution be inspected to confirm it is clear and free of particulate before use. These are not stylistic preferences; inconsistent handling can reduce potency and reintroduce exactly the outcome variability the protocol is meant to eliminate.

Labeling, Storage, and Beyond-Use Dating

Once a vial is reconstituted it becomes a time-limited, temperature-sensitive, identity-critical object. The three jobs of this section of your SOP are to label it so anyone can identify it, store it so it stays viable, and date it so no one uses it past its window.

Storage before reconstitution

Unopened Botox, Dysport, and Jeuveau vials are stored refrigerated at 2°C to 8°C. Daxxify is the exception: its unopened vials may be kept at room temperature (20°C to 25°C) or refrigerated, in the original carton to protect from light. Your SOP should specify a refrigerator temperature log, a designated medication refrigerator (not a break-room unit), and a procedure for what happens if the cold chain is broken — for example, after a power loss. Because Daxxify breaks the "everything lives in the fridge" habit, its storage rule should be posted where staff can see it.

Beyond-use dating after reconstitution

Manufacturer labeling for Botox directs that reconstituted product be used within 24 hours, stored refrigerated at 2°C to 8°C, and never frozen; Dysport and Jeuveau carry the same 24-hour refrigerated limit. Some published stability research suggests reconstituted toxin may retain potency considerably longer under controlled conditions, but a med spa SOP should follow the manufacturer beyond-use date as the default. If your medical director chooses to extend it on the basis of evidence, that decision must be written, justified, and owned by the physician — not adopted informally to reduce waste. The reconstitution date and time must be written directly on the vial label so any provider can confirm at a glance that a vial is still within its beyond-use window. A vial with no reconstitution time on it should be discarded, not guessed at.

Vial Handling: Single vs Multi-Patient

The aesthetic neurotoxins are labeled as single-dose, single-patient products. Daxxify's labeling is the most explicit, directing that each reconstituted vial be used for only one patient in only one injection session and that any remaining solution be discarded immediately after administration. The practical pressure runs the other way — a 100-unit vial often exceeds what one patient needs, and the temptation to draw from it for a second patient is real. That temptation is precisely where infection-control and compliance risk live.

Drawing from one vial for multiple patients introduces cross-contamination risk, conflicts with manufacturer instructions and USP standards for handling, and is a serious finding in any inspection or lawsuit. Your SOP should state the practice standard plainly — the safest and most defensible being single vial, single patient, single session — and pair it with consistent aseptic technique: alcohol swabbing the stopper, a new sterile needle for each draw, and never re-entering a vial that has been used for another patient. The economics of waste are real, but they are an inventory and scheduling problem to solve with vial-size selection and appointment batching, not by compromising vial handling. For the broader aseptic framework, see our med spa infection control protocol guide.

Dosing Documentation an SOP Must Capture

If standardization is the goal, the dosing record is the proof. Free-text notes like "Botox to forehead" do not survive an audit. A neurotoxin SOP should mandate a structured dosing record — ideally a template field in the EHR — capturing every element below for every treatment.

1. Product brand and generic name — e.g., Dysport (abobotulinumtoxinA), not just "tox"
2. Lot or batch number — the link to traceability and recall response
3. Vial expiration date — confirming the product was in date
4. Diluent type and volume — preserved vs preservative-free saline, and the mL used
5. Resulting concentration — units per 0.1 mL after reconstitution
6. Reconstitution date and time — proving the vial was within its beyond-use window
7. Total units administered — the overall dose for the session
8. Units per anatomic area — distribution across treatment zones
9. Conversion ratio applied — when switching from the practice's anchor brand
10. Treating provider and supervising physician — who performed and who oversaw

Captured together, these fields tie each dose to a specific vial, support recall and adverse-event reporting, and demonstrate that the same standard was applied regardless of which provider treated the patient. Pair the dosing record with a product-specific consent that names the brand used — our guide to Botox consent forms for med spas covers what that consent should disclose.

The format matters as much as the content. Lot numbers, expiration dates, and reconstitution times recorded as free text in a progress note are easy to omit and hard to query later. The same data captured in discrete, required EHR fields — or on a paper dosing-log template that cannot be signed off incomplete — turns documentation from a memory test into a workflow that fails safely. When a provider physically cannot close the chart without a lot number, the lot number gets recorded. That is the difference between a policy that exists on paper and one that actually governs behavior at the point of care. A practical anchor is the recall test: if a manufacturer announced a recall of a specific lot tomorrow, could you produce, within an hour, a list of every patient who received product from that lot? If the honest answer is no, your dosing documentation is not yet doing its job.

Switching Brands Safely (Conversion Pitfalls)

Practices switch neurotoxin brands for cost, supply, or clinical reasons, and switching is where conversion errors cluster. The danger is muscle memory: a provider who doses Botox in the 20–40 unit range may carry that mental model to Dysport and dramatically under-dose, or carry a Dysport number back to Botox and over-dose. The error is rarely a clinical knowledge gap — it is a standardization gap.

A safe switching protocol has a few non-negotiables. First, the unit-equivalence reference must be physically present and current wherever injections happen. Second, the chart must record the brand and the conversion ratio used, every time, so the math is auditable. Third, any brand change at the practice level should trigger a short documented re-training — even a 15-minute huddle with a sign-off sheet — so every provider is converting the same way. Fourth, the patient should be told when their brand is changing, and that should be reflected in the consent and the chart, because duration and re-treatment expectations differ. None of this is injection technique; all of it is documentation discipline that prevents a predictable error.

Supply-driven substitution deserves special attention because it is the least planned. When a preferred product is back-ordered and a practice swaps brands mid-week, the conversion error risk spikes precisely because the change was reactive rather than scheduled. The SOP should anticipate this: a standing rule that any substitution — even a temporary one — follows the same documented conversion reference and charting requirement as a planned switch, with no informal "we'll just match the old number" shortcut. A back-order is an inventory event, but the way you handle the dose is still a clinical-documentation event, and the two should never be allowed to collapse into a guess.

Building a Neurotoxin Handling SOP

Pulling the preceding sections together, a complete neurotoxin handling SOP — reviewed and signed by your medical director — should contain the following components:

• Product roster — every neurotoxin the practice stocks, with vial sizes and a brand-specific handling note for each
• Unit-equivalence reference — the practice's approved conversion ratios, dated and physician-signed
• Reconstitution standard — diluent type, dilution volume per product, target concentration, and gentle-technique instructions
• Labeling standard — what goes on the vial label, including reconstitution date and time
• Storage and cold-chain policy — temperatures, refrigerator logging, Daxxify room-temperature exception, and cold-chain-failure procedure
• Beyond-use dating — the manufacturer default and any physician-approved deviation, with justification
• Vial-handling rule — single-patient standard and aseptic technique
• Dosing-documentation template — the mandatory fields for every treatment record
• Brand-switching protocol — re-training trigger and charting requirements
• Adverse-event and recall pathway — how lot traceability feeds reporting
• Review and signature block — version date and medical director sign-off, reviewed at least annually

The SOP does not replace clinical judgment about how to inject — it standardizes everything around the injection so that judgment is exercised consistently and is documented in a way that holds up. Most practices do not have the bandwidth to author this from scratch correctly, which is why a pre-written, physician-reviewable kit is the common path. Sibling complications guidance lives in our dermal filler complications guide and the forthcoming Botox complications management companion.

Common Dosing and Reconstitution Mistakes

The errors below recur across practices precisely because they are habits, not knowledge gaps — and habits are what an SOP exists to override.

• Charting units without the brand. "40 units" is meaningless six months later in a record review. Always pair the number with the product.
• Assuming 1:1 conversion. Carrying Botox numbers to Dysport (or vice versa) is the most dangerous and most common error. Use the written reference, every time.
• Inconsistent dilution between providers. Two concentrations for the same product means two different treatments and unpredictable spread.
• No reconstitution time on the vial. Without it, beyond-use dating becomes a guess — and an indefensible one.
• Treating Daxxify like the others. Its room-temperature storage allowance and distinct unit scale break the patterns staff learn elsewhere.
• Reusing a vial across patients. An infection-control and labeling violation that is hard to defend regardless of intent.
• Missing lot numbers. Without lot capture, a recall or adverse-event investigation has no thread to pull.
• Off-label diluent with no documented decision. Preserved saline is a reasonable choice — but only when the medical director has adopted it in writing.

Every item on that list is closed by a single written standard plus a structured dose record. None of it requires a more skilled injector — it requires a more disciplined system.